|Pulmatrix Inc -- USA Stock|| |
USD 1.92 0.02 1.05%
Chairman of the Board, CEO, Chief Science Officer
Mr. Hojabr Alimi has served as our Chief Executive Officer Chief Science Officer and Chairman of our Board of Directors since February 4 2013. Mr. Alimi was also appointed Chairman of our board of directors on that same date. From 1999 to February 2013 Mr. Alimi held the position of President and Chief Executive Officer at our former parent company Oculus a public company which he cofounded with his spouse. Mr. Alimi served as Chairman of the Board of Oculus from 1999 until February 2014. Upon completion of our initial public offering Mr. Alimi resigned from Oculus board of directors. Prior to founding Oculus Mr. Alimi was a corporate microbiologist for Arterial Vascular Engineering
Age: 52 Chairman Since 2013
Alimi received a B.A. in biology from Sonoma State University.
The company has return on total asset (ROA)
of (38.77) %
which means that it has lost $38.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (122.79) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 4.55 M in liabilities with Debt to Equity (D/E) ratio of 28.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix Inc has Current Ratio of 1.95 which is within standard range for the sector.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix Inc (PULM) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 18 people. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.